Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity [6]

Leukemia

Volumn 21, Issue 6, 2007, Pages 1310-1312

  Zahiragic, L ^a   Schliemann, C ^a   Bieker, R ^a   Thoennissen, N H ^a   Burow, K ^a   Kramer, C ^a   Zuhlsdorf M ^a   Berdel, W E ^a   Mesters, R M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CLEMASTINE; CYTARABINE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MITOXANTRONE; PARACETAMOL; RANITIDINE; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTERY THROMBOSIS; BLEEDING; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPERTENSIVE CRISIS; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; RETREATMENT; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

EID: 34249721065     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404632     Document Type: Letter

References (7)

1. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302-1310.
2. Gerber HP, Ferrera N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 57: 4593-4599.
3. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
4. Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241-243.
5. Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688-5695.
6. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-3294, Epub 23 December 2004.
7. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577-3585.